In addition to the recommendations, the report addresses several frequently asked questions about antidepressant treatment during pregnancy. In evaluating the cumulative research related to antidepressant use in pregnancy, the authors noted several limitations. Specifically, few of the studies that assessed associations between antidepressant treatment and birth outcomes included information on maternal psychiatric illness and confounding factors that influence birth outcomes, such as poor prenatal care and drug, alcohol, and nicotine use, which occur at a higher rate among depressed vs. nondepressed women, were often not controlled.
Some of the report authors disclosed having received research support and consultants fees from various pharmaceutical companies, including Eli Lilly, Pfizer, Wyeth, Boehringer Ingelheim, Bayer Schering Pharma AG, Berlex, and GlaxoSmithKline.